Medera and Novoheart collaborate on mini-heart models for HLHS
Medera and its subsidiary Novoheart have collaborated with scientists at the University of California San Diego School of Medicine and…
Cardiovascular
-
-
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for…
-
CirCode Biomed gains clearance from FDA for RNA drug HM2002
CirCode Biomed’s circular RNA drug HM2002 has received investigational new drug (IND) clearance from the US Food and Drug Administration…
-
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid)…
-
Haya secures $65m in Series A funds to advance heart failure treatment
Haya Therapeutics has procured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure.…
-
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis under the name…
-
ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patients
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by O’Neill and colleagues…
-
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the…
-
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851,…
-
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the investigational oral small molecule lipoprotein(a)…
